DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration
CERTIFICATION: FINANCIAL INTERESTS AND ARRANGEMENTS OF CLINICAL INVESTIGATORS	Form Approved: OMB No. 0910-0396
Expiration Date: August 31, 2012	
TO BE COMPLETED BY APPLICANT	

With respect to all covered clinical studies (or specific clinical studies listed below (if appropriate)) submitted in support of this application, I certify to one of the statements below as appropriate. I understand that this certification is made in compliance with 21 CFR part 54 and that for the purposes of this statement, a clinical investigator includes the spouse and each dependent child of the investigator as defined in 21 CFR 54.2(d).

Please mark the applicable checkbox.

(1) As the sponsor of the submitted studies, I certify that I have not entered into any financial arrangement with the listed clinical investigators (enter names of clinical investigators below or attach list of names to this form) whereby the value of compensation to the investigator could be affected by the outcome of the study as defined in 21 CFR 54.2(a). I also certify that each listed clinical investigator required to disclose to the sponsor whether the investigator had a proprietary interest in this product or a significant equity in the sponsor as defined in 21 CFR 54.2(b) did not disclose any such interests. I further certify that no listed investigator was the recipient of significant payments of other sorts as defined in 21 CFR 54.2(f).

(2) As the applicant who is submitting a study or studies sponsored by a firm or party other than the applicant, I certify that based on information obtained from the sponsor or from participating clinical investigators, the listed clinical investigators (attach list of names to this form) did not participate in any financial arrangement with the sponsor of a covered study whereby the value of compensation to the investigator for conducting the study could be affected by the outcome of the study (as defined in 21
CFR 54.2(a)); had no proprietary interest in this product or significant equity interest in the sponsor of the covered study (as defined in 21 CFR 54.2(b)); and was not the recipient of significant payments of other sorts (as defined in 21 CFR 54.2(f)).

(3) As the applicant who is submitting a study or studies sponsored by a firm or party other than the applicant, I certify that I have acted with due diligence to obtain from the listed clinical investigators (attach list of names) or from the sponsor the information required under 54.4 and it was not possible to do so. The reason why this information could not be obtained is attached.	
Paperwork Reduction Act Statement
An agency  may not conduct  or sponsor,  and a person  is not required  to respond  to, a collection  of
information  unless it displays a currently valid OMB control number. Public reporting burden for this 	Department of Health and Human Services collection  of information  is estimated  to average  1 hour  per response,  including  time  for  reviewing 	Food and Drug Administration
instructions,   searching   existing  data  sources,   gathering   and  maintaining   the  necessary   data,  and 	Office of Chief Information Officer completing and reviewing the collection of information. Send comments regarding this burden estimate 	1350 Piccard Drive, 420A
or any other aspect of this collection of information to the address to the right: 	Rockville, MD 20850	

Clinical Investigators			

NAME	TITLE	
FIRM/ORGANIZATION	
SIGNATURE	DATE (mm/dd/yyyy)	

FORM FDA 3454 (7/12)

PSC Graphics (301) 443-1090      EF